Levels and significance of pepsinogen, gastrin 17 in serum in patients with chronic atrophic gastritis

Objective To analyze the levels of serum pepsinogen, gastrin 17 (G-17) in patients with chronic atrophic gastritis and their clinical significance. Methods A total of 196 patients with gastroduodenal disease who underwent gastroscopy in Linfen Central Hospital from January 2016 to January 2019 were selected as the study objects. According to the results of gastroscopy, they were divided into chronic atrophic gastritis group and non-atrophic gastritis group, with 98 cases in each group. The patients in chronic atrophic gastritis group were further divided into atrophic gastric body inflammation group (34 cases), atrophic gastric antrum inflammation group (42 cases), and the whole atrophic gastric multifocal gastritis group (22 cases) according to the lesion sites. The levels of serum pepsinogen Ⅰ (PG Ⅰ), pepsinogen Ⅱ (PG Ⅱ) and G-17 were measured by enzyme-linked immunosorbent assay. And pepsinogen ratio (PGR), PG Ⅰ/PG Ⅱ, was calculated. Qualitative detection of Helicobacter pylori (Hp) was performed by 13C urea breath test. The levels of PGⅠ, PGⅡ, PGR, and G-17 in each group were analyzed and compared among groups. Results The levels of serum PG Ⅰ and G-17 in the chronic atrophic gastritis group were significantly lower than those in the non-atrophic gastritis group (P 0.05), the difference in PGR between the two groups was statistically significant (P 0.05). Conclusions Decreased levels of PGⅠ, PGR and G-17 are biological markers of chronic atrophic gastritis. Large-scale population screening and screening for chronic atrophic gastritis can be performed based on serum PGⅠ and PGR cutoffs, and further examination with gastroscopy can improve the early diagnostic rate of gastric cancer. Key words: Stomach neoplasms; Chronic atrophic gastritis; Pepsinogen I; Pepsinogen Ⅱ; Gastrin 17; Pepsinogen ratio